Research Article
Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
Table 1
Inclusion criteria for RSV immunoprophylaxis (palivizumab).
| Inclusion criteria | Age at the start of RSV season |
| Gestational age ≤28 weeks | ≤12 months | Gestational age ≥29 to <32 weeks | ≤6 months | Gestational age ≥32 to <35 weeks | ≤6 months and RSV high-risk score of ≥49 | Hemodynamically significant CHD, CCF, pulmonary hypertension, etc. | ≤6 months | CLD who required medical therapy or required medical treatment within preceding 6 months before starting RSV season | ≤24 months | Congenital anomaly of airways or neuromuscular diseases that compromise handling of respiratory secretions | ≤24 months | Cystic fibrosis, immunocompromised | ≤24 months (case by case basis) |
|
|
RSV, respiratory syncytial virus; CHD, congenital heart disease; CCF; congestive cardiac failure.
|